文献速递头颈与中枢神经肿瘤

局部晚期鼻咽癌同步放化疗后辅助卡培他滨:一项随机临床试验

Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2022-10-13

这项在中国3家机构开展的开放标签随机临床试验,纳入180例局部晚期鼻咽癌患者,评估同步放化疗后辅助卡培他滨对比观察的疗效与安全性。中位随访58.0个月,卡培他滨组无失败生存优于对照组(5年78.5% vs 65.9%,HR 0.53,95%CI 0.30-0.94,P=0.03),3级治疗相关不良事件发生率两组相近。

要点

  • 同步放化疗后辅助卡培他滨改善高危局部晚期鼻咽癌的无失败生存(HR 0.53)。
  • 卡培他滨组5年无失败生存78.5%,对照组65.9%,3年分别为83.3%和72.2%。
  • 卡培他滨组3级治疗相关不良事件60.0%,对照组51.1%,以口干、黏膜炎、厌食为主。

核心结论

  • 在局部晚期鼻咽癌高危患者中,同步放化疗后辅助全剂量卡培他滨耐受良好,并改善无失败生存。
  • 作者认为需进一步研究评估最佳剂量和疗程。

研究设计与样本

  • 开放标签随机临床试验,2014年3月31日至2018年7月27日在中国3家机构招募患者,随访至少3年,数据收集截止2022年2月9日。
  • 共纳入180例III-IVb期鼻咽癌患者,按1:1随机分为卡培他滨组和观察组,每组90例。
  • 卡培他滨方案为1000 mg/m2每日两次,每3周用14天,共8个周期;同步放化疗为顺铂100 mg/m2每3周,2至3个周期。
  • 主要终点为意向治疗人群的无失败生存,采用Kaplan-Meier曲线和log-rank检验比较。

主要发现

  • 中位随访58.0个月(IQR 49.5-80.1),卡培他滨组记录18例事件,对照组31例事件。
  • 无失败生存卡培他滨组优于对照组:3年83.3% vs 72.2%,5年78.5% vs 65.9%,HR 0.53(95%CI 0.30-0.94),P=0.03。
  • 3级治疗相关不良事件发生率卡培他滨组60.0%(54/90)vs 对照组51.1%(46/90)。
  • 治疗相关不良事件包括口干(18.9% vs 10.0%)、黏膜炎(23.3% vs 16.7%)、厌食(8.9% vs 4.4%)。
  • 3级迟发性治疗相关不良事件两组相近:10.8%(9/83) vs 8.6%(7/81)。

关键数值与推荐

  • 入组条件为III-IVb期鼻咽癌,且至少满足以下一项:T3-4N2或T1-4N3;血浆EBV DNA滴度高于20000 copies/mL;原发肿瘤大体体积大于30.0 cm3;FDG PET/CT原发肿瘤大体体积最大标准摄取值大于10.0;多个淋巴结转移且任一大于4.0 cm。
  • 卡培他滨组90例中85例(94.4%)接受卡培他滨,71例(78.9%)完成8个周期。
  • 卡培他滨组90例中76例(84.4%)有至少2个高危因素,对照组90例中80例(88.9%)有至少2个高危因素。

临床怎么用

  • 对于局部晚期鼻咽癌高危患者,同步放化疗后辅助卡培他滨可作为改善无失败生存的治疗选择。
  • 卡培他滨组3级治疗相关不良事件发生率高于对照组,用药期间需关注口干、黏膜炎和厌食等不良反应。

局限性

  • 作者认为需进一步研究评估最佳剂量和疗程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Induction or adjuvant chemotherapy with concurrent chemoradiotherapy (CCRT) are first-line treatment options for treatment of locoregionally advanced nasopharyngeal carcinoma (LA-NPC). Adjuvant platinum regimens are, however, poorly tolerated, highlighting the unmet need for an efficacious, tolerable adjuvant regimen. OBJECTIVE: To investigate the efficacy and safety of adjuvant capecitabine with CCRT for the treatment of patients with LA-NPC. DESIGN, SETTING, AND PARTICIPANTS: This open-label randomized clinical trial recruited patients from March 31, 2014, to July 27, 2018, at 3 institutions in China, with at least 3 years of follow-up. The data collection cutoff date was February 9, 2022. Eligibility included stage III-IVb nasopharyngeal carcinoma and at least 1 of the following: T3-4N2 or T1-4N3; plasma Epstein-Barr virus DNA titer higher than 20 000 copies/mL; primary gross tumor volume larger than 30.0 cm3; fluorodeoxyglucose F 18 positron emission tomography/computed tomography maximum standard uptake value of the primary gross tumor volume larger than 10.0; or multiple nodal metastases and any larger than 4.0 cm. INTERVENTIONS: Patients were randomly assigned 1:1 to receive either capecitabine (1000 mg/m2 twice daily for 14 days every 3 weeks for 8 cycles) or observation following CCRT (100 mg/m2 cisplatin every 3 weeks for 2 to 3 cycles, depending on duration of radiotherapy). MAIN OUTCOMES AND MEASURES: Failure-free survival in the intention-to-treat cohort was assessed using Kaplan-Meier survival curves compared with the log-rank test. Unstratified Cox proportional hazards regression models were used to estimate hazard ratios, with corresponding 95% CIs based on the Wald test. RESULTS: There were 180 patients enrolled (median [IQR] age, 47 [40-55] years; 143 [79.4%] men). Among 90 patients in the capecitabine group, 76 (84.4%) had at least 2 high-risk factors; among 90 patients in the control group, 80 (88.9%) had at least 2 high-risk factors. All patients completed CCRT, except 1 patient in the capecitabine group who received 1 cycle of cisplatin. Of the 90 patients in the capecitabine group, 85 (94.4%) received capecitabine, with 71 (78.9%) completing 8 cycles. With a median (IQR) follow-up of 58.0 (49.5-80.1) months, 18 events were recorded in the capecitabine group vs 31 events in the control group. Failure-free survival was improved with adjuvant capecitabine (3 years, 83.3% vs 72.2%; 5 years, 78.5% vs 65.9%; hazard ratio, 0.53 [95% CI, 0.30-0.94]; P = .03). The incidence of grade 3 treatment-related adverse events (TRAEs) was higher in the capecitabine group than in the control group (54 of 90 patients [60.0%] vs 46 of 90 patients [51.1%]). Treatment-related adverse events included xerostomia (17 [18.9%] vs 9 [10.0%] patients), mucositis (21 [23.3%] vs 15 [16.7%] patients), and anorexia (8 [8.9%] vs 4 [4.4%] patients). The incidence of grade 3 delayed treatment-related adverse events was comparable in both groups (9 of 83 [10.8%] vs 7 of 81 [8.6%] patients). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, adjuvant capecitabine at the full dose following CCRT was well tolerated and improved failure-free survival among patients with LA-NPC and high-risk factors. Further investigations assessing optimal dose and duration are warranted. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02143388.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Miao J, Wang L, Tan SH, et al. Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Clinical Trial. JAMA Oncol. 2022. PMID: 36227615. doi:10.1001/jamaoncol.2022.4656

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。